Literature DB >> 20851342

Halogen bonds form the basis for selective P-TEFb inhibition by DRB.

Sonja Baumli1, Jane A Endicott, Louise N Johnson.   

Abstract

Cdk9, the kinase of the positive transcription elongation factor b, is required for processive transcription elongation by RNA polymerase II. Cdk9 inhibition contributes to the anticancer activity of many Cdk inhibitors under clinical investigation and hence there is interest in selective Cdk9 inhibitors. DRB (5,6-dichlorobenzimidazone-1-β-D-ribofuranoside) is a commonly used reagent for Cdk9 inhibition in cell biology studies. The crystal structures of Cdk9 and Cdk2 in complex with DRB reported here describe the molecular basis for the DRB selectivity toward Cdk9. The DRB chlorine atoms form halogen bonds that are specific for the Cdk9 kinase hinge region. Kinetic and thermodynamic experiments validate the structural findings and implicate the C-terminal residues of Cdk9 in contributing to the affinity for DRB. These results open the possibility to exploit halogen atoms in inhibitor design to specifically target Cdk9.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851342     DOI: 10.1016/j.chembiol.2010.07.012

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  29 in total

1.  A quantum mechanics-based halogen bonding scoring function for protein-ligand interactions.

Authors:  Zhuo Yang; Yingtao Liu; Zhaoqiang Chen; Zhijian Xu; Jiye Shi; Kaixian Chen; Weiliang Zhu
Journal:  J Mol Model       Date:  2015-05-10       Impact factor: 1.810

2.  Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity?

Authors:  Olivier Bensaude
Journal:  Transcription       Date:  2011-05

3.  Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.

Authors:  Hozefa S Bandukwala; John Gagnon; Susan Togher; Jason A Greenbaum; Edward D Lamperti; Nigel J Parr; Amy M H Molesworth; Nicholas Smithers; Kevin Lee; Jason Witherington; David F Tough; Rab K Prinjha; Bjoern Peters; Anjana Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-21       Impact factor: 11.205

4.  HEXIM1 controls satellite cell expansion after injury to regulate skeletal muscle regeneration.

Authors:  Peng Hong; Kang Chen; Bihui Huang; Min Liu; Miao Cui; Inna Rozenberg; Brahim Chaqour; Xiaoyue Pan; Elisabeth R Barton; Xian-Cheng Jiang; M A Q Siddiqui
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

5.  Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.

Authors:  Jelena Randjelović; Slavica Erić; Vladimir Savić
Journal:  J Mol Model       Date:  2013-01-08       Impact factor: 1.810

6.  Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).

Authors:  Alexander D MacKerell; Sunhwan Jo; Sirish Kaushik Lakkaraju; Christoffer Lind; Wenbo Yu
Journal:  Biochim Biophys Acta Gen Subj       Date:  2020-01-03       Impact factor: 3.770

7.  Use of Phenoxyaniline Analogues To Generate Biochemical Insights into the Interactio n of Polybrominated Diphenyl Ether with CYP2B Enzymes.

Authors:  Chao Chen; Jingbao Liu; James R Halpert; P Ross Wilderman
Journal:  Biochemistry       Date:  2017-12-19       Impact factor: 3.162

8.  Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.

Authors:  Jiadi Gao; Cheng Fang; Zhiyan Xiao; Li Huang; Chin-Ho Chen; Li-Ting Wang; Kuo-Hsiung Lee
Journal:  Medchemcomm       Date:  2015-03-01       Impact factor: 3.597

Review 9.  Structure-based discovery of cyclin-dependent protein kinase inhibitors.

Authors:  Mathew P Martin; Jane A Endicott; Martin E M Noble
Journal:  Essays Biochem       Date:  2017-11-08       Impact factor: 8.000

10.  Structure-kinetic relationship study of CDK8/CycC specific compounds.

Authors:  Elisabeth V Schneider; Jark Böttcher; Robert Huber; Klaus Maskos; Lars Neumann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.